by 
The pain patch market comprises medicated adhesive patches that deliver pain relief through transdermal drug delivery. Pain patches contain various active pharmaceutical ingredients (APIs) such as lidocaine, diclofenac, buprenorphine, fentanyl, and nitroglycerin, and are used to treat various types of acute and chronic pain caused by arthritis, sport injuries, lower back pain and postoperative and neuropathic pain. Technological advancements in transdermal drug delivery systems have enhanced the efficacy of pain patches by improving skin permeability and controlling drug release kinetics.
The global pain patch market is estimated to be valued at US$ 5.29 Bn in 2023 and is expected to exhibit a CAGR of 5% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The pain patch market is expected to flourish owing to the growing prevalence of chronic diseases that cause chronic pain such as arthritis and lower back pain. According to the Centers for Disease Control and Prevention, around 60% of US adults suffer from back pain, making it the most common cause of job-related disability. Transdermal patches provide relief from chronic pain without gastric irritation caused by oral medication and reduce the dosing frequency, thereby improving patient compliance. In addition, the increasing demand for long-acting non-invasive treatments is also projected to surge the demand for pain patches over the forecast period. However, the development of drug resistance and adverse effects related to certain pain patches may restrain the market growth.
Segment Analysis
The global pain patch market can be segmented based on therapeutic pain type as neuropathic pain, cancer pain, musculoskeletal pain and others. The neuropathic pain segment dominates the market currently and accounts for over 30% of the global pain patch market share owing to the high prevalence of neuropathic pain associated with diabetes, shingles and post-herpetic neuralgia. This segment is expected to witness high growth during the forecast period as well due to growing cases of neuropathic pain worldwide and rising demand for effective pain management treatment options.
PEST Analysis
Political: Regulations around the sale and use of pain patches varies across countries and regions which can impact the market growth. However, growth of public health insurance is positively impacting the adoption of innovative pain management products.
Economic: Rising healthcare spending driven by growing economy and disposable income is one of the key factors fueling the growth of pain patch market. Additionally, growing elderly population susceptible to chronic pain further supports market growth.
Social: Increasing awareness about pain management options and benefits of non-invasive therapies is driving the preference for pain patches over oral pills and topical creams. Furthermore, busy lifestyle has increased the demand for easy to use on-the-go pain relief products.
Technological: Continued investment in R&D is leading to development of advanced drug delivery systems and new formulation technologies in pain patches for improved efficacy and alternative site applications beyond regular body areas. Transdermal patches integrated with wearables is also gaining traction.
Key Takeaways
The global pain patch market size was valued at US$ 5.29 Bn in 2023 and expanding at a CAGR of 5%.
Regionally, North America commanded the largest share in 2023 owing to robust healthcare infrastructure and high adoption of innovative pain therapeutics. Europe and Asia Pacific are also promising markets and anticipated to witness fastest growth during the forecast period driven by growing awareness, focus on non-opioid therapies, and expanding patient pool in developing countries.
Key players operating in the pain patch market are Hisamitsu Pharmaceutical Co., Inc., Johnson & Johnson, Pfizer Inc., Novartis AG, Mylan N.V. Hisamitsu Pharmaceutical Co., Inc. leads the market with its popular Salonpas Pain Relief Patch with menthol. The company also launched transdermal pain patches with lidocaine and diclofenac for various types of pain. Johnson & Johnson’s Tylenol Pain Relieving Patch and Nicoderm CQ Nicotine Patch are other top selling products. Pfizer’s Flector Patch, Acorda Therapeutics’ Parkinson’s disease patch, and Mylan’s fentanyl pain patch have also gained traction in recent years.
*Note:
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.
